<DOC>
	<DOCNO>NCT02203253</DOCNO>
	<brief_summary>This study aim evaluate efficacy tolerability thalidomide improve prevention chemotherapy-induced delayed nausea vomit chemotherapy-naive patient highly emetogenic chemotherapy .</brief_summary>
	<brief_title>Efficacy Thalidomide Preventing Chemotherapy-induced Delayed Nausea Vomiting</brief_title>
	<detailed_description>This prospective , randomize , multi-center , double-blind , placebo-controlled clinical trial , aim evaluate efficacy tolerability thalidomide improve prevention chemotherapy-induced delayed nausea vomiting ( CINV ) chemotherapy-naive patient highly emetogenic chemotherapy ( HEC ) ( cisplatin-based regimen cyclophosphamide combination doxorubicin/epirubicin ) . A total 820 patient plan enrol study . Patients treat highly emetogenic chemotherapy randomize two group , treat Thalidomide+ Palonosetron+ Dexamethasone Placebo + Palonosetron+ Dexamethasone , respectively . The primary end point complete response rate ( CRR ) delay CINV , secondary end point include safety quality life ( QOL ) .</detailed_description>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Palonosetron</mesh_term>
	<criteria>18y ≤Age≤70y Eastern Cooperative Oncology Group ( ECOG ) Performance Status 02 Histologically confirm solid neoplasm No prior chemotherapy Laboratory test must meet following criterion : hemoglobin ( HGB ) ≥90g/L , neutrophil count ≥1.5×109/L , platelet count ≥85×109/L , creatinine clearance rate ( CCr ) ≥60ml/min , total bilirubin ( TBil ) ≤1.5 upper normal limitation ( UNL ) , alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤2.5 UNL ( For patient liver metastasis , AST/ALT must ≤5.0 UNL ) , blood glucose ≤11.1 mmol/L Life expectancy least 12 week Signed informed consent For woman child bear potential , negative serum urine pregnancy test result obtain enrollment Cancer patient schedule receive HEC regimen . The HEC regimen define chemotherapy contain 50 mg/m2 high dose cisplatin , cyclophosphamide combination doxorubicin/epirubicin Diabetic patient Pregnant lactated woman Patient history thrombosis Concomitant radiotherapy Known hypersensitivity thalidomide , palonosetron , dexamethasone . Concurrent administration drug affect antiemetic effect evaluation proton pump inhibitor , H2 blocker , amifostine , sedative drug CHOP regiment taxanesbased regiment Existing emesis within 24 hour chemotherapy administration Symptomatic brain metastasis suspect clinical brain metastasis Serious uncontrolled systemic illness medical condition : congestive heart failure , unstable angina , history document myocardial infarction within 6 month , uncontrolled hypertension high risk uncontrollable arrhythmia ; Obvious neurological mental abnormality include mental disorder , epileptic dementia , affect compliance ; Uncontrolled acute infection ; Uncontrolled peptic ulcer contraindication corticosteroid therapy . Inability take absorb oral medicine Concurrent administration investigational drug , enrol clinical trial investigational drug treatment within 30 day start study treatment Unsuitable study chemotherapy determine investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>solid tumor</keyword>
	<keyword>chemotherapy-induced delay nausea vomit</keyword>
	<keyword>thalidomide</keyword>
	<keyword>prevention</keyword>
</DOC>